GlassScriptPhysician profile
Ori A Rackovsky
NPI 1245505601
$2,064.89
in general payments reported to CMS, 2019-2025
21 companies · $600 in 2025
The $600 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $236 · 2020: $53.32 · 2021: $215 · 2022: $325 · 2023: $341 · 2024: $295 · 2025: $600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,219 · Education: $16.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,219.20 |
| Education | $16.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $785.59 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $200.01 | 2020-2025 | Xifaxan |
| Qol Medical, LLC | $156.34 | 2019-2025 | Sucraid |
| Janssen Biotech, INC. | $122.92 | 2020-2025 | Tremfya, Stelara |
| Ironwood Pharmaceuticals, INC | $119.89 | 2019-2021 | |
| Gilead Sciences, INC. | $104.33 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $97.58 | 2019-2025 | Gattex, Eohilia, Entyvio |
| Capsovision, INC. | $72.40 | 2023-2024 | Capsocam Plus |
| Celgene Corporation | $71.78 | 2021-2023 | Zeposia |
| Ardelyx, INC. | $67.63 | 2023-2024 | Ibsrela |
| Aimmune Therapeutics, INC. | $59.69 | 2025 | Zenpep |
| Regeneron Healthcare Solutions, INC. | $39.60 | 2025 | Dupixent |
| Braintree Laboratories, INC. | $29.25 | 2021-2024 | Suflave |
| Phathom Pharmaceuticals, INC. | $26.69 | 2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $21.18 | 2023 | Rebyota |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $19.54 | 2025 | |
| Madrigal Pharmaceuticals | $16.15 | 2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $14.93 | 2022 | |
| Merck Sharp & Dohme LLC | $14.69 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $12.84 | 2019 | |
| Shionogi INC | $11.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ori Rackovsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.